As a large proportion of people taking medications like Mounjaro, Ozempic and Wegovy for weight loss report consuming less ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to treat type 2 diabetes and, in some cases, obesity. "The glucagon-like peptide (GLP-1 ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat type 2 diabetes and obesity.

Further research is needed to better understand their use. The addition of glucagon-like peptide-1 receptor agonists to progestin therapy may help reduce endometrial cancer risk among certain ...

a glucagon-like peptide (GLP-1) receptor agonist, reduces the risk for major adverse cardiovascular events, according to SOUL, an international phase 3b placebo-controlled trial. The result is ...

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 ...

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

nonusers. GLP-1 receptor agonist use was associated with 49% lower incidence of graft loss. For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists ...